Literature DB >> 19252051

Research risk for persons with psychiatric disorders: a decisional framework to meet the ethical challenge.

Philip T Yanos1, Barbara S Stanley, Carolyn S Greene.   

Abstract

OBJECTIVE: There is a lack of consensus on how to evaluate the risk of research studies conducted with persons who have psychiatric disorders. The authors reviewed research on vulnerability, risk, and procedures to mitigate risk in studies with this population to help inform evaluation of such research.
METHODS: Searches of MEDLINE (1966-2006), PsycINFO (1967-2006), and Google Scholar used combinations of the terms mental illness, vulnerable, psychiatric, schizophrenia, and depression combined with terms such as research risk, vulnerability, research harm, capacity, risk, and mitigation of risk. Articles were identified from reference lists, and additional searches used terms from identified articles.
RESULTS: Evidence for two types of vulnerability--capacity based and power based--is presented, which supports the notion of vulnerability as a state, rather than a trait, among persons with psychiatric disorders. Three categories of risk are described--minimal risk, minor increment over minimal risk, and greater than minor increment. Evidence shows that many common types of studies pose risk in the first two categories when conducted with this population. The literature also describes procedures for reducing vulnerability and mitigating risk that should be considered in study evaluations. The authors offer a framework for evaluating the category of risk posed by a study.
CONCLUSIONS: Although more research is needed, there is sufficient evidence that many common types of research present minimal risk or only a minor increment over minimal risk for large segments of the population of persons with psychiatric disorders, as they do for persons in the general population.

Entities:  

Mesh:

Year:  2009        PMID: 19252051      PMCID: PMC2865129          DOI: 10.1176/ps.2009.60.3.374

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   4.157


  39 in total

1.  Psychological and social risks of behavioral research.

Authors:  Susan M Labott; Timothy P Johnson
Journal:  IRB       Date:  2004 May-Jun

2.  Historical vulnerability and special scrutiny: precautions against discrimination in medical research.

Authors:  Anita Silvers
Journal:  Am J Bioeth       Date:  2004       Impact factor: 11.229

Review 3.  Capacity to consent to research in schizophrenia: the expanding evidence base.

Authors:  Laura B Dunn
Journal:  Behav Sci Law       Date:  2006

4.  Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument.

Authors:  Barton W Palmer; Laura B Dunn; Paul S Appelbaum; Sunder Mudaliar; Leon Thal; Robert Henry; Shahrokh Golshan; Dilip V Jeste
Journal:  Arch Gen Psychiatry       Date:  2005-07

5.  Do research procedures pose relatively greater risk for healthy persons than for persons with schizophrenia?

Authors:  Laura Weiss Roberts; Laura B Dunn; Katherine A Green Hammond; Teddy D Warner
Journal:  Schizophr Bull       Date:  2005-09-15       Impact factor: 9.306

6.  Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions.

Authors:  Laura Weiss Roberts; Teddy D Warner; Janet L Brody; Brian Roberts; John Lauriello; Constantine Lyketsos
Journal:  Am J Psychiatry       Date:  2002-04       Impact factor: 18.112

7.  Assessments by patients with schizophrenia and psychiatrists of relative risk of research procedures.

Authors:  Laura Weiss Roberts; Teddy D Warner; Katherine Green Hammond; Laura B Dunn
Journal:  Psychiatr Serv       Date:  2006-11       Impact factor: 3.084

8.  An inverse relationship between perceived harm and participation willingness in schizophrenia research protocols.

Authors:  Laura Weiss Roberts; Katherine Green Hammond; Jinger Hoop
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

9.  Clinical impact of a 2-week psychotropic medication washout in unipolar depressed inpatients.

Authors:  Michael F Grunebaum; Maria A Oquendo; Ainsley K Burke; Steven P Ellis; Gonzalo Echavarria; Beth S Brodsky; Kevin M Malone; J John Mann
Journal:  J Affect Disord       Date:  2003-08       Impact factor: 4.839

10.  Preliminary findings on psychiatric patients as research participants: a population at risk?

Authors:  B Stanley; M Stanley; A Lautin; J Kane; N Schwartz
Journal:  Am J Psychiatry       Date:  1981-05       Impact factor: 18.112

View more
  6 in total

1.  Prototype matching together with operational criteria would make a better approach to psychiatric classification.

Authors:  Pichet Udomratn
Journal:  World Psychiatry       Date:  2012-02       Impact factor: 49.548

2.  Is there a universal understanding of vulnerability? Experiences with Russian and Romanian trainees in research ethics.

Authors:  Sana Loue; Bebe Loff
Journal:  J Empir Res Hum Res Ethics       Date:  2013-12       Impact factor: 1.742

3.  Patient-Centered Outcomes Research (PCOR): How Can We Optimize Outcomes in CNS Research?

Authors:  Mitali Wadekar; Anil Sharma; Gina Battaglia
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

4.  No regrets: Young adult patients in psychiatry report positive reactions to biobank participation.

Authors:  Janet L Cunningham; Manuel Zanzi; Mimmie Willebrand; Lisa Ekselius; Mia Ramklint
Journal:  BMC Psychiatry       Date:  2017-01-17       Impact factor: 3.630

5.  Applying Genetic and Genomic Tools to Psychiatric Disorders: A Scoping Review.

Authors:  Ana S IItis; Akaya Lewis; Sarah Neely; Stephannie Walker Seaton; Sarah H Jeong
Journal:  HEC Forum       Date:  2021-11-30

Review 6.  Informed consent, genomic research and mental health: A integrative review.

Authors:  Nina Kilkku; Arja Halkoaho
Journal:  Nurs Ethics       Date:  2022-02-04       Impact factor: 3.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.